As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff

John Carroll

Editor & Founder

Almost exactly 2 years ago, Orchard Therapeutics execs reorganized the pipeline, shed staff and circled their wagons around what they considered the most vital part …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff

John Carroll

Editor & Founder

Sign up to read this article for free.

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Coherus makes final, $483M pivot away from biosimilars

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals

As shares tank, Or­chard once again re­struc­tures, shed­ding gene ther­a­py pro­grams and a large part of the staff

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

GSK ter­mi­nates Phase 2 tri­al of HBV ther­a­peu­tic vac­cine

Co­herus makes fi­nal, $483M piv­ot away from biosim­i­lars

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

As shares tank, Orchard once again restructures, shedding gene therapy programs and a large part of the staff

Lilly drops body mass ranges from FDA label for weight loss drug

GSK terminates Phase 2 trial of HBV therapeutic vaccine

Coherus makes final, $483M pivot away from biosimilars

Janux soars on early prostate cancer data that could challenge Novartis' Pluvicto

Ipsen secures rights to preclinical T cell engager in $610M pact with French biotech

Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals